Hematologic Oncology Update, Issue 1, 2016 (Video Program)Key prognostic factors in Hodgkin lymphoma (HL)
1:06 minutes.
TRANSCRIPTION:
DR YOUNES: There are several prognostic factors that are widely used for stratification for clinical trials. Unfortunately, none of them is a perfect science. So the old-fashioned IPS, the International Prognostic Score, can sort out who is less likely to be cured or not. But even the worst prognostic group in this system, they have about a cure rate of 50%. So it’s not like a zero versus 100%. It just gives you an idea that they have a lower chance of being cured than others, but they’re still a highly cured group of patients. The second method that is used to predict is using interim PET scanning. So usually, if you achieve a PET-negative status after 2 cycles of standard therapy, such as ABVD, chances that you’ll be cured is much higher than those who have PET-positive status. But again, if you have a PET-positive disease after 2 cycles of ABVD, there is a fraction of patients that can still be cured, up to 40% to 50% of these patients. So again, it’s not perfect science but gives you an idea who’s less likely to be cured and who’s more highly likely to be cured. |